4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results